Canada markets closed

NIO Inc. (NIO)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
4.5000-0.1700 (-3.64%)
At close: 04:00PM EDT
4.5200 +0.02 (+0.44%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close4.6700
Open4.6800
Bid4.4900 x 312300
Ask4.5200 x 38800
Day's Range4.4800 - 4.7400
52 Week Range4.4500 - 16.1800
Volume54,430,351
Avg. Volume58,394,675
Market Cap9.405B
Beta (5Y Monthly)1.94
PE Ratio (TTM)N/A
EPS (TTM)-1.7300
Earnings DateJun 07, 2024 - Jun 11, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks

    A Closer Look at China's Changing EV Landscape

    The once-booming EV market in China is experiencing a slowdown due to economic challenges and reduced government subsidies, prompting a shift in strategy among local and international automakers.

  • GlobeNewswire

    NIO Inc. Prudently Adjusts First Quarter 2024 Delivery Outlook

    SHANGHAI, China, March 27, 2024 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the premium smart electric vehicle market, today provided an updated delivery outlook for the first quarter of 2024. Based on the most recent business update, the Company expects to deliver approximately 30,000 vehicles in the first quarter of 2024, revised from the previous outlook of 31,000 to 33,000 vehicles. About NIO Inc. NIO Inc. is a p

  • Yahoo Finance Video

    Tesla, Lucid, Novo Nordisk: Trending tickers

    EV makers Tesla (TSLA), Rivian (RIVN), and NIO (NIO) have all received a downgrade from Mizuho Securities to Neutral citing near-term demand and challenges with liquidity going into next year. Shares of Lucid (LCID) are jumping Monday morning after the EV maker announced a $1 billion investment from its majority stockholder, Ayar Third Investment Company, to buy newly created convertible preferred stocks.  Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals, a company that develops RNA-based therapeutics for heart disease. The deal includes a heart failure treatment in phase two of clinical development Yahoo Finance Anchors Madison Mills and Seana Smith break down the latest developments for these companies. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.Editor's note: This article was written by Nicholas Jacobino